Inventiva S.A. (NASDAQ: IVA) Stock Competitors & Peer Comparison
See IVA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IVA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IVA | $3.78 | +0.80% | 196.5M | -1.28 | -$2.96 | N/A |
| VRTX | $508.34 | -1.55% | 129B | 26.70 | $19.03 | N/A |
| REGN | $784.85 | -0.58% | 80.9B | 17.20 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $990.32 | -0.55% | 61.6B | 89.38 | $11.08 | N/A |
| MRNA | $154.04 | -2.55% | 61.1B | -18.90 | -$8.15 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $190.95 | -3.04% | 40.6B | -21.64 | -$8.82 | N/A |
| RVMDW | $9.64 | -6.36% | 38.3B | -1.11 | -$8.82 | N/A |
| ONC | $350.84 | -0.74% | 37.5B | 61.77 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
IVA vs VRTX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, VRTX has a market cap of 129B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while VRTX trades at $508.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas VRTX's P/E ratio is 26.70. In terms of profitability, IVA's ROE is +18.38%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, IVA is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
IVA vs REGN Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, REGN has a market cap of 80.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while REGN trades at $784.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas REGN's P/E ratio is 17.20. In terms of profitability, IVA's ROE is +18.38%, compared to REGN's ROE of +0.14%. Regarding short-term risk, IVA is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for IVA.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
IVA vs VRNA Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IVA's ROE is +18.38%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, IVA is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for IVA.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
IVA vs ARGX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ARGX trades at $990.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ARGX's P/E ratio is 89.38. In terms of profitability, IVA's ROE is +18.38%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, IVA is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
IVA vs MRNA Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, MRNA has a market cap of 61.1B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while MRNA trades at $154.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas MRNA's P/E ratio is -18.90. In terms of profitability, IVA's ROE is +18.38%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, IVA is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for IVA.Check MRNA's competition here
Seagen Inc. (NASDAQ: SGEN)
IVA vs SGEN Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IVA's ROE is +18.38%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IVA is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for IVA.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
IVA vs RVMD Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, RVMD has a market cap of 40.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while RVMD trades at $190.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas RVMD's P/E ratio is -21.64. In terms of profitability, IVA's ROE is +18.38%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, IVA is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for IVA.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
IVA vs RVMDW Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, RVMDW has a market cap of 38.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while RVMDW trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas RVMDW's P/E ratio is -1.11. In terms of profitability, IVA's ROE is +18.38%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, IVA is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for IVA.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
IVA vs ONC Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ONC has a market cap of 37.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ONC trades at $350.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ONC's P/E ratio is 61.77. In terms of profitability, IVA's ROE is +18.38%, compared to ONC's ROE of +0.14%. Regarding short-term risk, IVA is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
IVA vs ALNY Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ALNY has a market cap of 32.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ALNY trades at $239.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ALNY's P/E ratio is 44.24. In terms of profitability, IVA's ROE is +18.38%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, IVA is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
IVA vs ROIV Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ROIV has a market cap of 28.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ROIV trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ROIV's P/E ratio is -37.84. In terms of profitability, IVA's ROE is +18.38%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, IVA is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
IVA vs INSM Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, INSM has a market cap of 26B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while INSM trades at $120.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas INSM's P/E ratio is -29.20. In terms of profitability, IVA's ROE is +18.38%, compared to INSM's ROE of -1.11%. Regarding short-term risk, IVA is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for IVA.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
IVA vs INCY Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, INCY has a market cap of 25.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while INCY trades at $125.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas INCY's P/E ratio is 16.84. In terms of profitability, IVA's ROE is +18.38%, compared to INCY's ROE of +0.30%. Regarding short-term risk, IVA is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for IVA.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
IVA vs BNTX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, BNTX has a market cap of 24.1B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while BNTX trades at $96.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas BNTX's P/E ratio is -12.46. In terms of profitability, IVA's ROE is +18.38%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, IVA is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
IVA vs GMAB Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while GMAB trades at $34.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas GMAB's P/E ratio is 26.18. In terms of profitability, IVA's ROE is +18.38%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, IVA is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for IVA.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
IVA vs UTHR Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, UTHR has a market cap of 21B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while UTHR trades at $494.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas UTHR's P/E ratio is 17.70. In terms of profitability, IVA's ROE is +18.38%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, IVA is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for IVA.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
IVA vs BGNE Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IVA's ROE is +18.38%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, IVA is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for IVA.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
IVA vs DNA-WT Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IVA's ROE is +18.38%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, IVA is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for IVA.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
IVA vs JAZZ Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while JAZZ trades at $240.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas JAZZ's P/E ratio is 8.98. In terms of profitability, IVA's ROE is +18.38%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, IVA is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for IVA.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
IVA vs NBIX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, NBIX has a market cap of 14.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while NBIX trades at $146.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas NBIX's P/E ratio is 21.13. In terms of profitability, IVA's ROE is +18.38%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, IVA is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for IVA.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
IVA vs ASND Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ASND trades at $236.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ASND's P/E ratio is -97.82. In terms of profitability, IVA's ROE is +18.38%, compared to ASND's ROE of +1.90%. Regarding short-term risk, IVA is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
IVA vs EXEL Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while EXEL trades at $58.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas EXEL's P/E ratio is 16.67. In terms of profitability, IVA's ROE is +18.38%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, IVA is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for IVA.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
IVA vs SMMT Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, SMMT has a market cap of 14.2B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while SMMT trades at $17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas SMMT's P/E ratio is -15.94. In terms of profitability, IVA's ROE is +18.38%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, IVA is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for IVA.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
IVA vs HALO Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, HALO has a market cap of 13.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while HALO trades at $112.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas HALO's P/E ratio is 20.98. In terms of profitability, IVA's ROE is +18.38%, compared to HALO's ROE of +1.81%. Regarding short-term risk, IVA is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for IVA.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
IVA vs BBIO Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while BBIO trades at $66.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas BBIO's P/E ratio is -17.81. In terms of profitability, IVA's ROE is +18.38%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, IVA is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for IVA.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
IVA vs KRTX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IVA's ROE is +18.38%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IVA is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
IVA vs BMRN Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while BMRN trades at $63.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas BMRN's P/E ratio is 30.74. In terms of profitability, IVA's ROE is +18.38%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, IVA is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for IVA.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
IVA vs MDGL Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while MDGL trades at $531.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas MDGL's P/E ratio is -41.52. In terms of profitability, IVA's ROE is +18.38%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, IVA is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for IVA.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
IVA vs TECH Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while TECH trades at $72.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas TECH's P/E ratio is 37.30. In terms of profitability, IVA's ROE is +18.38%, compared to TECH's ROE of +0.09%. Regarding short-term risk, IVA is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for IVA.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
IVA vs RNAM Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IVA's ROE is +18.38%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IVA is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for IVA.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
IVA vs AXSM Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while AXSM trades at $207.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas AXSM's P/E ratio is -54.25. In terms of profitability, IVA's ROE is +18.38%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, IVA is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for IVA.Check AXSM's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
IVA vs TWST Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, TWST has a market cap of 10.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while TWST trades at $166.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas TWST's P/E ratio is -75.22. In terms of profitability, IVA's ROE is +18.38%, compared to TWST's ROE of -0.30%. Regarding short-term risk, IVA is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for IVA.Check TWST's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
IVA vs KRYS Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while KRYS trades at $336.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas KRYS's P/E ratio is 42.19. In terms of profitability, IVA's ROE is +18.38%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IVA is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for IVA.Check KRYS's competition here
10x Genomics, Inc. (NASDAQ: TXG)
IVA vs TXG Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, TXG has a market cap of 9.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while TXG trades at $76.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas TXG's P/E ratio is -129.83. In terms of profitability, IVA's ROE is +18.38%, compared to TXG's ROE of -0.09%. Regarding short-term risk, IVA is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for IVA.Check TXG's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
IVA vs KYMR Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while KYMR trades at $117.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas KYMR's P/E ratio is -36.80. In terms of profitability, IVA's ROE is +18.38%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, IVA is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for IVA.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
IVA vs RXDX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IVA's ROE is +18.38%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IVA is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check RXDX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
IVA vs ARWR Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ARWR has a market cap of 9.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ARWR trades at $66.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ARWR's P/E ratio is -29.55. In terms of profitability, IVA's ROE is +18.38%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, IVA is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ARWR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
IVA vs PTGX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, PTGX has a market cap of 9.2B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while PTGX trades at $143.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas PTGX's P/E ratio is 138.83. In terms of profitability, IVA's ROE is +18.38%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, IVA is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
IVA vs NUVL Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas NUVL's P/E ratio is -21.79. In terms of profitability, IVA's ROE is +18.38%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IVA is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for IVA.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
IVA vs CRNX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CRNX's P/E ratio is -16.86. In terms of profitability, IVA's ROE is +18.38%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IVA is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
IVA vs IBRX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while IBRX trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas IBRX's P/E ratio is -8.74. In terms of profitability, IVA's ROE is +18.38%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, IVA is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check IBRX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
IVA vs IMGN Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IVA's ROE is +18.38%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IVA is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for IVA.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
IVA vs TGTX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, TGTX has a market cap of 8.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while TGTX trades at $56.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas TGTX's P/E ratio is 20.61. In terms of profitability, IVA's ROE is +18.38%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, IVA is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check TGTX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
IVA vs CYTK Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CYTK trades at $68.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CYTK's P/E ratio is -9.53. In terms of profitability, IVA's ROE is +18.38%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, IVA is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for IVA.Check CYTK's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
IVA vs CAI Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CAI has a market cap of 8.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CAI trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CAI's P/E ratio is 84.24. In terms of profitability, IVA's ROE is +18.38%, compared to CAI's ROE of +0.19%. Regarding short-term risk, IVA is similarly volatile compared to CAI. This indicates similar risk in terms of short-term price fluctuations for IVA.Check CAI's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
IVA vs PCVX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while PCVX trades at $58.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas PCVX's P/E ratio is -7.62. In terms of profitability, IVA's ROE is +18.38%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, IVA is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for IVA.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
IVA vs BPMC Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IVA's ROE is +18.38%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, IVA is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for IVA.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
IVA vs APGE Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas APGE's P/E ratio is -31.19. In terms of profitability, IVA's ROE is +18.38%, compared to APGE's ROE of -0.30%. Regarding short-term risk, IVA is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for IVA.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
IVA vs PRAX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while PRAX trades at $298.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas PRAX's P/E ratio is -23.12. In terms of profitability, IVA's ROE is +18.38%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, IVA is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for IVA.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
IVA vs CERE Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CERE's P/E ratio is -16.47. In terms of profitability, IVA's ROE is +18.38%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IVA is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for IVA.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
IVA vs SYRE Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, SYRE has a market cap of 7.8B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while SYRE trades at $90.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas SYRE's P/E ratio is -46.28. In terms of profitability, IVA's ROE is +18.38%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, IVA is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for IVA.Check SYRE's competition here
Abivax S.A. (NASDAQ: ABVX)
IVA vs ABVX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ABVX trades at $105.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ABVX's P/E ratio is -55.06. In terms of profitability, IVA's ROE is +18.38%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, IVA is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ABVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
IVA vs IMVT Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while IMVT trades at $36.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas IMVT's P/E ratio is -13.10. In terms of profitability, IVA's ROE is +18.38%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, IVA is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for IVA.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
IVA vs MTSR Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IVA's ROE is +18.38%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, IVA is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for IVA.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
IVA vs IONS Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while IONS trades at $44.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas IONS's P/E ratio is -25.84. In terms of profitability, IVA's ROE is +18.38%, compared to IONS's ROE of -1.11%. Regarding short-term risk, IVA is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for IVA.Check IONS's competition here
Belite Bio, Inc (NASDAQ: BLTE)
IVA vs BLTE Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while BLTE trades at $170.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas BLTE's P/E ratio is -91.42. In terms of profitability, IVA's ROE is +18.38%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, IVA is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for IVA.Check BLTE's competition here
Merus N.V. (NASDAQ: MRUS)
IVA vs MRUS Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IVA's ROE is +18.38%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, IVA is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for IVA.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
IVA vs ACLX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IVA's ROE is +18.38%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IVA is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ACLX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
IVA vs RYTM Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while RYTM trades at $97.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas RYTM's P/E ratio is -31.42. In terms of profitability, IVA's ROE is +18.38%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, IVA is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for IVA.Check RYTM's competition here
CG Oncology Inc. (NASDAQ: CGON)
IVA vs CGON Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CGON trades at $74.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CGON's P/E ratio is -27.74. In terms of profitability, IVA's ROE is +18.38%, compared to CGON's ROE of -0.25%. Regarding short-term risk, IVA is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for IVA.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
IVA vs RETA Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas RETA's P/E ratio is -66.29. In terms of profitability, IVA's ROE is +18.38%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IVA is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for IVA.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
IVA vs CNTA Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CNTA's P/E ratio is -22.63. In terms of profitability, IVA's ROE is +18.38%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IVA is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for IVA.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
IVA vs TVTX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while TVTX trades at $62.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas TVTX's P/E ratio is -139.47. In terms of profitability, IVA's ROE is +18.38%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, IVA is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check TVTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
IVA vs ORKA Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ORKA has a market cap of 5.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ORKA trades at $94.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ORKA's P/E ratio is -48.95. In terms of profitability, IVA's ROE is +18.38%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, IVA is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ORKA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
IVA vs LGND Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while LGND trades at $283.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas LGND's P/E ratio is 31.12. In terms of profitability, IVA's ROE is +18.38%, compared to LGND's ROE of +0.20%. Regarding short-term risk, IVA is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for IVA.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
IVA vs CDTX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IVA's ROE is +18.38%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, IVA is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
IVA vs MIRM Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while MIRM trades at $91.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas MIRM's P/E ratio is -6.31. In terms of profitability, IVA's ROE is +18.38%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, IVA is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for IVA.Check MIRM's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
IVA vs SRRK Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while SRRK trades at $46.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas SRRK's P/E ratio is -13.52. In terms of profitability, IVA's ROE is +18.38%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, IVA is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for IVA.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
IVA vs ABCM Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IVA's ROE is +18.38%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IVA is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
IVA vs ISEE Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IVA's ROE is +18.38%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IVA is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ISEE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
IVA vs PTCT Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while PTCT trades at $65.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas PTCT's P/E ratio is -28.06. In terms of profitability, IVA's ROE is +18.38%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, IVA is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for IVA.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
IVA vs CRSP Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CRSP trades at $56.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CRSP's P/E ratio is -11.88. In terms of profitability, IVA's ROE is +18.38%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, IVA is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for IVA.Check CRSP's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
IVA vs DNTH Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while DNTH trades at $96.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas DNTH's P/E ratio is -23.33. In terms of profitability, IVA's ROE is +18.38%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, IVA is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for IVA.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
IVA vs COGT Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while COGT trades at $31.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas COGT's P/E ratio is -14.93. In terms of profitability, IVA's ROE is +18.38%, compared to COGT's ROE of -0.73%. Regarding short-term risk, IVA is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for IVA.Check COGT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
IVA vs APLS Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas APLS's P/E ratio is 38.35. In terms of profitability, IVA's ROE is +18.38%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IVA is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for IVA.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
IVA vs DFTX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while DFTX trades at $38.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas DFTX's P/E ratio is N/A. In terms of profitability, IVA's ROE is +18.38%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, IVA is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check DFTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
IVA vs ERAS Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ERAS trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ERAS's P/E ratio is -15.88. In terms of profitability, IVA's ROE is +18.38%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, IVA is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for IVA.Check ERAS's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
IVA vs EWTX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while EWTX trades at $45.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas EWTX's P/E ratio is -24.50. In terms of profitability, IVA's ROE is +18.38%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, IVA is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
IVA vs PBLS Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, PBLS has a market cap of 4.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while PBLS trades at $41.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas PBLS's P/E ratio is -47.42. In terms of profitability, IVA's ROE is +18.38%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, IVA is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for IVA.Check PBLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
IVA vs TERN Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas TERN's P/E ratio is -51.41. In terms of profitability, IVA's ROE is +18.38%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IVA is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for IVA.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
IVA vs ACAD Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ACAD trades at $27.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ACAD's P/E ratio is 12.29. In terms of profitability, IVA's ROE is +18.38%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, IVA is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
IVA vs IOVA Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, IOVA has a market cap of 4.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while IOVA trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas IOVA's P/E ratio is -14.04. In terms of profitability, IVA's ROE is +18.38%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, IVA is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for IVA.Check IOVA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
IVA vs ADPT Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ADPT trades at $28.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ADPT's P/E ratio is -69.63. In terms of profitability, IVA's ROE is +18.38%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, IVA is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
IVA vs FOLD Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IVA's ROE is +18.38%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IVA is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for IVA.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
IVA vs AKRO Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IVA's ROE is +18.38%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, IVA is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for IVA.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
IVA vs ALPN Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IVA's ROE is +18.38%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IVA is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for IVA.Check ALPN's competition here
Veradermics, Incorporated (NYSE: MANE)
IVA vs MANE Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while MANE trades at $106.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas MANE's P/E ratio is -33.96. In terms of profitability, IVA's ROE is +18.38%, compared to MANE's ROE of -0.38%. Regarding short-term risk, IVA is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for IVA.Check MANE's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
IVA vs TLX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, TLX has a market cap of 4.3B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while TLX trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas TLX's P/E ratio is 131.42. In terms of profitability, IVA's ROE is +18.38%, compared to TLX's ROE of +0.07%. Regarding short-term risk, IVA is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check TLX's competition here
Opthea Limited (NASDAQ: OPT)
IVA vs OPT Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas OPT's P/E ratio is -1.52. In terms of profitability, IVA's ROE is +18.38%, compared to OPT's ROE of +1.18%. Regarding short-term risk, IVA is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for IVA.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
IVA vs PRTC Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas PRTC's P/E ratio is -3.78. In terms of profitability, IVA's ROE is +18.38%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, IVA is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for IVA.Check PRTC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
IVA vs RLAY Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while RLAY trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas RLAY's P/E ratio is -12.00. In terms of profitability, IVA's ROE is +18.38%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, IVA is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for IVA.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
IVA vs MRTX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IVA's ROE is +18.38%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IVA is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
IVA vs CELC Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CELC trades at $80.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CELC's P/E ratio is -18.75. In terms of profitability, IVA's ROE is +18.38%, compared to CELC's ROE of -3.51%. Regarding short-term risk, IVA is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for IVA.Check CELC's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
IVA vs ABCL Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while ABCL trades at $12.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas ABCL's P/E ratio is -23.39. In terms of profitability, IVA's ROE is +18.38%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, IVA is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for IVA.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
IVA vs CPRX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CPRX's P/E ratio is 12.30. In terms of profitability, IVA's ROE is +18.38%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IVA is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for IVA.Check CPRX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
IVA vs XENE Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while XENE trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas XENE's P/E ratio is -8.46. In terms of profitability, IVA's ROE is +18.38%, compared to XENE's ROE of -0.44%. Regarding short-term risk, IVA is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for IVA.Check XENE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
IVA vs AMLX Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, AMLX has a market cap of 3.8B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while AMLX trades at $32.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas AMLX's P/E ratio is -22.63. In terms of profitability, IVA's ROE is +18.38%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, IVA is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for IVA.Check AMLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
IVA vs RYZB Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IVA's ROE is +18.38%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IVA is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for IVA.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
IVA vs CBAY Comparison September 2026
Inventiva S.A. (NASDAQ: IVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 196.5M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IVA is priced at $3.78 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.28, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IVA's ROE is +18.38%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IVA is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for IVA.Check CBAY's competition here